
A landmark ruling in Sydney on February 15 gave the biotechnology industry an unprecedented right to make huge profits from genetic testing.
The case involved the breast cancer genes BRCA 1 and BRCA 2 and the right of US biotechnology company Myriad Genetics to have exclusive licence to a patent over their use in research.
Federal Court Justice John Nicholas had ruled that a private company can continue to hold a patent over an isolated gene, in this case, the BRCA gene. The BRCA gene is responsible for repairing or removing defective DNA cells.